drugset / Trial / NCT04719221

Impact of Evolocumab as an Additional Lipid-lowering Therapy to Changes in Lipid Core Burden Index of Non-culprit Vulnerable Plaque in Patients Who Underwent Percutaneous Coronary Intervention for the Acute Coronary Syndrome

NCT04719221

Phase 4 Unknown 60 enrolled Korea University Anam Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

This study aimed to investigate the impact of intensive cholesterol-lowering therapy (including evolocumab), drug treatment for high-risk plaques (Vulnerable plaques) with a high probability of developing acute coronary syndrome. The purpose of this study is to determine the effect of the change in the Lipid core burden index and compare the rate of cardiac events over 12 months following cholesterol therapy.

Timeline

Start
2021-03-01
Primary completion
2024-12
Completion
2024-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Evolocumab Monoclonal antibody